-$0.24 EPS Expected for Dicerna Pharmaceuticals Inc (DRNA) This Quarter
Analysts expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to announce earnings per share of ($0.24) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.28). Dicerna Pharmaceuticals posted earnings of ($0.92) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 73.9%. The company is expected to issue its next quarterly earnings results on Thursday, November 1st.
Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.79 million.
NASDAQ DRNA traded down $0.81 during trading hours on Tuesday, reaching $15.99. 1,378,292 shares of the stock traded hands, compared to its average volume of 830,546. Dicerna Pharmaceuticals has a 1 year low of $4.19 and a 1 year high of $17.98. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.40 and a current ratio of 5.40.
In other news, insider James B. Weissman sold 2,301 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $17.50, for a total value of $40,267.50. Following the transaction, the insider now owns 26,781 shares in the company, valued at $468,667.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Dennis Langer sold 14,531 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $16.00, for a total value of $232,496.00. Following the completion of the transaction, the director now owns 29,064 shares in the company, valued at approximately $465,024. The disclosure for this sale can be found here. Company insiders own 19.85% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in DRNA. Cubist Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $102,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $113,000. Caxton Corp purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $125,000. Jane Street Group LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $136,000. Finally, Verition Fund Management LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $141,000. Hedge funds and other institutional investors own 87.02% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Featured Article: Penny Stocks, Risk and Reward Factors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.